CSIMarket


Eucrates Biomedical Acquisition Corp   (EUCR)
Other Ticker:  
 
    Sector  Financial    Industry Blank Checks
   Industry Blank Checks
   Sector  Financial


 

Eucrates Biomedical Acquisition Corp

EUCR's Financial Statements and Analysis



Eucrates Biomedical Acquisition Corp reported in the forth quarter of 2022 net earnings per share of $0.04 an increase by 297.93 % year on year from $0.01 and an improvement of 8.7 % from $0.04 realized in III. Quarter (Sep 30 2022).


forth quarter of 2022
Earnings Per Share Revenues
$ 0.04 $  0 Mill
$+0.03     +297.93 % Unch.    



Eucrates Biomedical Acquisition 's Revenue fell by 0 % in forth quarter of 2022 (Dec 31 2022) year on year, to $0 million and declined by sequentially.


Eucrates Biomedical Acquisition is Expected to report next financial results on April 12, 2024.

More on EUCR's Income Statement



Eucrates Biomedical Acquisition 's net income of $0.142 million in the forth quarter of 2022 decreased by -43.13 % from net earnings of $0.249 million achieved in IV. Quarter a year ago.

Sequentially net earnings fell by -72.81 % from net income of $0.521 million realized in previous quarter.

More on EUCR's Growth

Eucrates Biomedical Acquisition Inventories
In Dec 31 2022 company's net cash and cash equivalents decreased by $0 million


Eucrates Biomedical Acquisition Corp does not pay out common stock dividend.

In trailing twelve-month period Eucrates Biomedical Acquisition Corp payed $ -0.05 cash per share, on a free-cash flow basis .


Tangible Book value grew to $ -0.32 per share from $ -0.36.

Company issued 1.04 million shares or 9.95 % in Dec 31 2022.
Debt Coverage Ratio was 19.53.

More on EUCR's Dividends

 Market Capitalization (Millions) 116
 Shares Outstanding (Millions) 12
 Total Debt (Millions $) 0
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 2
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Eucrates Biomedical Acquisition Corp does not pay out common stock dividend.

In trailing twelve-month period Eucrates Biomedical Acquisition Corp had negative $ -0.05 cash flow per share, on a free-cash flow basis .


Tangible Book value grew to $ -0.32 per share from $ -0.36.

Company issued 1.04 million shares or 9.95 % in Dec 31 2022.
Debt Coverage Ratio was 19.53.

More on EUCR's Balance Sheets

 Market Capitalization (Millions) 116
 Shares Outstanding (Millions) 12
 Total Debt (Millions $) 0
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 2
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   



Date modified: 2023-04-14T13:42:46+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com